Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (10401)	3/2/2004 10:07:13 PM
From: JMarcus	Respond to of 52153

POTP's 2004 goals, per last week's press release: biz.yahoo.com 1. Initiate four Phase 2 PT-100 clinical studies in three different oncology indications where PT-100 will be studied in combination with chemotherapeutic agents and monoclonal antibodies as well as a single agent anti-tumor therapeutic. 2. Complete the current Phase 1 PT-100/Rituxan® study. 3. Move from the OTC bulletin board to a NASDAQ SmallCap Market listing. Today the stock closed at the same 52-week closing high of $6.35 that had been reached on Feb. 19th. Here's hoping that the stock isn't in the process of completing a double-top formation. With ASCO being not far off, there's reason to hope for a showing of growing strength in biotechs focusing upon cancer therapeutics. Marc